Henry Schein (HSIC) Projected to Announce Earnings on Tuesday

Henry Schein (NASDAQ:HSIC) is expected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Henry Schein to post earnings of $1.36 per share and revenue of $3.48 billion for the quarter. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period last year, the business earned $1.10 earnings per share. The business’s revenue was up 6.7% on a year-over-year basis. On average, analysts expect Henry Schein to post $5.36 EPS for the current fiscal year and $5.94 EPS for the next fiscal year.

Henry Schein Price Performance

HSIC stock opened at $84.51 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. The firm has a 50 day moving average price of $86.85 and a 200-day moving average price of $80.94. Henry Schein has a 52-week low of $62.15 and a 52-week high of $92.18. The firm has a market capitalization of $9.42 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 1.53 and a beta of 0.84.

Analysts Set New Price Targets

HSIC has been the topic of several recent research reports. Barrington Research set a $104.00 price target on Henry Schein in a research note on Wednesday, August 5th. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Barclays reissued an “overweight” rating and issued a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Leerink Partners set a $92.00 target price on Henry Schein and gave the stock a “market perform” rating in a research note on Wednesday, October 14th. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Nine investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.27.

Henry Schein Company Profile

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.